Share on StockTwits
 

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith R. Leonard sold 12,740 shares of KYTHERA Biopharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $45.35, for a total transaction of $577,759.00. Following the completion of the sale, the chief executive officer now directly owns 52,452 shares of the company’s stock, valued at approximately $2,378,698. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded up 0.29% on Tuesday, hitting $45.55. The stock had a trading volume of 94,139 shares. KYTHERA Biopharmaceuticals has a 52-week low of $14.07 and a 52-week high of $47.85. The stock has a 50-day moving average of $40.72 and a 200-day moving average of $37.46. The company’s market cap is $974.8 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.10. Analysts expect that KYTHERA Biopharmaceuticals will post $-2.74 EPS for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.